High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.

Despite the development of new treatment options, the prognosis of high-risk neuroblastoma patients is still poor; more than half of patients experience disease recurrence. High-dose chemotherapy and haematopoietic stem cell rescue (i.e. myeloablative therapy) might improve survival.